

Abstract

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal
5 former; wherein the API has at least one functional group selected from ether, thioether,
alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate
ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid,
sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp²
10 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic
ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide,
peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least
one functional group selected from amine, amide, pyridine, imidazole, indole,
pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and
15 methyl thio, such that the API and co-crystal former are capable of co-crystallizing from
a solution phase under crystallization conditions.